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Abstract
Angiotensinogen (AGT) is a critical protein in the renin-angiotensin-aldosterone system and may have an important role in the
pathogenesis of pre-eclampsia. The disulphide linkage between cysteines 18 and 138 has a key role in the redox switch of AGT
which modulates the release of angiotensin I with consequential effects on blood pressure. In this paper, we report a quantitative
targeted LC-MS/MSmethod for the reliable measurement of the total AGTand its reduced and oxidised forms in human plasma.
AGT was selectively enriched from human plasma using two-dimensional chromatography employing concanavalin A lectin
affinity and reversed phase steps and then deglycosylated using PNGase F. A differential alkylation approach was coupled with
targeted LC-MS/MS method to identify the two AGT forms in the plasma chymotryptic digest. An additional AGT proteolytic
marker peptide was identified and used to measure total AGT levels. The developed MS workflow enabled the reproducible
detection of total AGTand its two distinct forms in human plasma with analytical precision of ≤ 15%. The LC-MS/MS assay for
total AGT in plasma showed a linear response (R2 = 0.992) with a limit of quantification in the low nanomolar range. The method
gave suitable validation characteristics for biomedical application to the quantification of the oxidation level and the total level of
AGT in plasma samples collected from normal and pre-eclamptic patients.
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Introduction
Cysteine (Cys) thiol plays a central role in protein structure
and redox signalling, and this importance is highlighted by its
involvement in many pathological conditions involving oxi-
dative stress [1], including neurodegenerative diseases [2] and
pre-eclampsia [3]. Angiotensinogen (AGT), Fig. 1, is a plas-
ma glycoprotein and an essential component of the renin-
angiotensin-aldosterone system (RAAS). The tail of AGT is
cleaved by the action of the enzyme renin, in response to
lowered blood pressure or increased sodium load at the mac-
ula densa, to yield the decapeptide angiotensin I, which is
further cleaved by angiotensin converting enzyme (ACE) to
generate the physiologically active octapeptide angiotensin II
resulting in an increase in blood pressure [4]. The crystal
structure of AGT revealed a key role for the disulphide linkage
between Cys18 and 138 in the redox switch of AGT that
modulates angiotensin release and, hence, potentially, blood
pressure. Normally, the ratio between the free thiol unbridged
form (reduced form) to the sulphydryl-bridged form (oxidised
form) of AGT is maintained in the circulation at 40:60
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respectively [3]. The oxidised form of AGT, compared to the
free thiol form, interacts with renin with fourfold higher bind-
ing affinity resulting in an increased generation of angiotensin
I and subsequently angiotensin II [3].
The crucial role of AGT in the RAAS has linked it with the
pathogenesis of pre-eclampsia, a multisystem pregnancy dis-
order characterised by hypertension and proteinuria develop-
ing after the 20th week of gestation [5] and one of the leading
causes of maternal and fetal mortality and morbidity world-
wide [6, 7]. Only two studies have revealed a significant de-
crease in the level of the reduced form of AGT (reflecting a
higher level of the oxidised form) in the plasma of pre-
eclamptic women compared to controls [3, 8], which could
be linked functionally to the increase in the blood pressure in
pre-eclampsia. Previously, due to the lack of specific antibod-
ies for the two distinct forms of AGT, prior quantification of
the oxidation level of AGT relied on the alkylation of the
reduced form of the protein and the use of a general antibody
for AGT (not specific for each form of AGT) [3, 8], which can
lead to inaccurate quantification. Although antibody-based
assays are highly sensitive and are available in convenient
high-throughput platforms, they suffer from poor selectivity
to discriminate between different protein isoforms [9].
Additionally, the process of developing a highly selective an-
tibody for a specific protein isoform is very challenging, ex-
pensive and time consuming [10, 11]. Therefore, there is a
need for an entirely new strategy that enables the detection
and the quantification of the two distinct forms of AGT, in the
plasma, with high sensitivity and selectivity.
Mass spectrometry (MS) is a well-recognised analytical
technique for protein identification, quantification and post-
translational modification characterisation including disulphide
linkage [12–14]. Targeted protein quantification by MS offers
several advantages over immunoassay methods. It is highly
multiplex and has shorter assay development timelines, lower
assay cost, improved reproducibility and precision and, of most
importance, higher specificity, which allows different structur-
ally related protein isoforms to be selectively measured [15].
The advances in MS-based protein analysis techniques, includ-
ing a range of variable redox analysis methodologies such as
redox differential gel electrophoresis [16], isotope-coded affin-
ity tags (ICAT) and differential alkylation [17, 18], and the
availability of several Cys-selective chemical probes have
considerably advanced redox protein analysis, and provided
researchers with the tools and workflows necessary to assess
thiol redox changes in complex biological systems [12–14].
Differential alkylation is the most common approach followed
for the identification and quantification of reversible cysteine
oxidations in proteins [17, 18]. In this approach, an initial irre-
versible alkylation of all free thiols with the first alkylating
agent is carried out to avoid any unwanted thiol–disulphide
exchange reactions that could affect the assessment of the oxi-
dation status. A subsequent reduction of the disulphide bond
and modification of the free thiols with a second alkylating
agent uniquely identifies the two protein states [18] (Fig. 2b).
Thiol-specific alkylation reagents (e.g. iodoacetamide (IAM)
and N-ethylmaleimide (NEM)) can be conjugated to a wide
variety of fluorophores and epitope tags for enrichment and
detection of the alkylated Cys. Stable-isotope-labelled
alkylating agents (e.g. d5-NEM, d4-IAM) are also available
which enhances the use of the differential alkylation approach
for redox protein detection and quantification [19].
The crucial role of the ratio of the two AGT forms in the
pathogenesis of pre-eclampsia and the lack of a reliable and
selective quantitative method that enables the identification
and the quantification of the oxidised and the reduced AGT
forms prompted us to develop and optimise, for the first time,
an MS-based method for the reliable detection of chymotryp-
tic peptides specific to the two AGT forms. We report here a
sample preparation workflow specific for the selective enrich-
ment and digestion of AGT from human plasma. A differen-
tial alkylation approach was coupled with targeted LC-MS/
MS to detect the oxidised and the reduced forms of AGT in
human plasma samples which were not detected by previous
antibody-based strategies.
Materials and methods
Selective enrichment of AGT by two-dimensional
chromatography using ConA lectin affinity
and reversed-phase modes
Glycoproteins were first extracted using lectin affinity chro-
matography. Concanavalin A-Sepharose 4B (ConA, Sigma-
Aldrich, UK) resin slurry (100μL) was placed into micro-tube
MRKRAPQSEM APAGVSLRAT ILCLLAWAGL AAGDRVYIHP FHLVIHNEST C18EQLAKANAG
KPKDPTFIPA PIQAKTSPVD EKALQDQLVL VAAKLDTEDK LRAAMVGMLA NFLGFRIYGM
HSELWGVVHG ATVLSPTAVF GTLASLYLGA LDHTADRLQA ILGVPWKDKN C138TSRLDAHKV
LSALQAVQGL LVAQGRADSQ AQLLLSTVVG VFTAPGLHLK QPFVQGLALY TPVVLPRSLD
FTELDVAAEK IDRFMQAVTG WKTGC232SLMGA SVDSTLAFNT YVHFQGKMKG FSLLAEPQEF
WVDNSTSVSV PMLSGMGTFQ HWSDIQDNFS VTQVPFTESA C308LLLIQPHYA SDLDKVEGLT
FQQNSLNWMK KLSPRTIHLT MPQLVLQGSY DLQDLLAQAE LPAILHTELN LQKLSNDRIR
VGEVLNSIFF ELEADEREPT ESTQQLNKPE VLEVTLNRPF LFAVYDQSAT ALHFLGRVAN
PLSTA
Fig. 1 Amino acid sequence of
AGT protein obtained from
Swiss-Prot database. Cys18 and
Cys138 are highlighted in bold
red font. Sequence starts from
RVYI…. presented in bold black
letters; the first 33 amino acids are
for the signal peptide
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filter devices (Spin-X®, Corning Inc.) to provide a 1:1 ratio of
resin bed to sample volume, and conditioned with 3 × 0.3 mL
washing buffer (50 mM TRIS pH 7.4, 0.15 M NaCl, 1 mM
CaCl2, MgCl2, MnCl2). The EDTA plasma samples (50 μL)
were diluted in 250 μL washing buffer, loaded onto the con-
ditioned resin and incubated at room temperature for 20 min
with agitation. The resin was washed three times with the
washing buffer to remove unbound proteins, and retained pro-
teins were eluted with 1.2 mL elution buffer (0.40 M methyl
α-D-mannopyranoside in washing buffer) for subsequent
reversed-phase solid-phase extraction (RP-SPE) fractionation.
The flow through the filter device was driven by centrifuga-
tion at 1000×g for 30 s in all steps.
Reversed-phase chromatography using RP-SPEwas applied
to extract AGT from glycoprotein plasma extract. Polymeric
large-pore RP-SPE cartridges (IST ISOLUTE, PDVB, C18
1000 Å, 25 mg) were wetted with 1 mL of 0.1% (v/v) TFA in
90% acetonitrile prior to conditioning with 1 mL of 0.1% TFA
in water. The enriched glycoprotein samples were loaded onto
the preconditioned SPE cartridge and washed with 1 mL 0.1%
TFA. The retained proteins were sequentially eluted with 1 mL
of 30, 35, 40, 43, 45, 48, 50, and 90% (v/v) acetonitrile in 0.1%
TFA in water, and the collected fractions were dried using vac-
uum centrifugation [20]. Human blood plasma was obtained
with informed consent following approval from the School of
Pharmacy Research Ethics Committee, University of
Nottingham, UK.
Monitoring AGT fractionation by Western blotting
The RP-SPE dried protein fractions were solubilised in SDS-
PAGE sample buffer (NuPAGE Fisher Scientific,
Loughborough, UK), and 20% of extracts were loaded onto 4–
12% Bis TRIS midi-format gels and electrophoresed according
to vendor guidelines. Proteins were electro-blotted in TRIS-
glycine buffer (20%methanol, 50mMpH7.6) to polyvinylidene
difluoride (PVDF)membrane. Immuno-detection of human plas-
ma AGT in RP-SPE fractions by Western blotting used mouse
Fig. 2 a Schematic representation
of the workflow followed in this
paper. Selective enrichment of
AGT from human plasma was
achieved using ConA Sepharose
followed by fractionation with
RP-SPE. The dried, collected RP-
SPE fraction, containing AGT,
was first deglycosylated with
PNGase F followed by differen-
tial alkylation and finally digested
using chymotrypsin. A targeted
LC-MS/MS method was used to
quantify signature peptides
indicative of total AGT plus its
oxidised and reduced forms in the
plasma. b A diagram for the
differential alkylation of the
reduced and oxidised AGT using
iodoacetamide (IAM) and
isotope-labelled IAM
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anti-human serpin A8/angiotensinogen antibody (MAB3156,
R&D Systems, UK) with horseradish-peroxidase-labelled anti-
mouse IgG, and visualised with tetramethylbenzidine
colourimetric reagent (Sigma-Aldrich, UK).
Deglycosylation and chymotryptic digestion
of enriched fractions of plasma AGT
The dried collected RP-SPE fractions containing AGT were
reconstituted in 50 μL 2 M urea in TRIS buffer (pH 7.4), and
proteins were deglycosylated using 1 μL PNGase F (P0705,
500,000 units/mL, glycerol free, New England Biolabs, UK)
for each 40 μg proteins. Deglycosylation was carried out for
1.5 h at 37 °C followed by alkylation of reduced AGT with
25 μL 200 mM IAM. The oxidised form of AGTwas reduced
first with 25 μL 50 mM DTT, and the free thiol was then
blocked with 25 μL 13C2,D2-IAM (98 atom% D, 99 atom%
13C, from Sigma-Aldrich, UK) to make the two AGT forms
mass distinguishable. All reactions were carried out at 37 °C
for 30 min in the dark using filter-assisted preparation (FASP)
(10 kDa Amicon Ultra 0.5, Sigma-Aldrich, UK). After each
reaction, the sample was washed twice with 400 μL of 50 mM
ammonium hydrogen carbonate at 14,000×g for 7 min. Prior
to digestion, the resulting 40 μL protein solution was diluted
to 100 μL with the same buffer. Protein digestion was carried
out using sequencing grade chymotrypsin (V106A, Promega,
UK) at 37 °C using an enzyme: protein ratio of 1:50 (w/w).
After 4 h, a second aliquot of chymotrypsin (1:100 enzyme to
rotein w/w) was added and digestion proceeded at 37 °C over-
night. The digestion reaction was quenched with 1% formic
acid, and NEM alkylated Cys18 peptide was added to 0.2 μM
net concentration as an internal standard. The samples were
then centrifuged for 5 min at 11,000×g, and the upper 90 μL
digest extract was submitted for LC-MS/MS analysis.
Detection of the oxidised and reduced forms of AGT
in the processed plasma samples using targeted
LC-MS/MS
Chymotrypsin produced signature peptides were analysed
using a 4000 QTRAP hybrid triple quadrupole/linear ion trap
mass spectrometer (Applied Biosystems, Foster City, CA,
USA) operating in positive ion mode. Peptides (10 μL of
digest extract) were first separated by a Shimadzu series
10AD VP LC system (Shimadzu, Columbia, MD) using a
C18, 300 Å, 100 × 1 mm, 3 μm column (ACE, Reading,
UK) and a mobile phase of water and acetonitrile both with
0.1% formic acid. A gradient from 10% to 45% (v/v) acetoni-
trile was developed over 10 min at 100 μL/min flow rate.
Synthetic peptides corresponding to unmodified and IAM
alkylated Cys18, Cys138 and AGT marker (Pierce Protein
Biological Products, Thermo Fisher Scientific, UK) were used
to optimise MS parameters and multiple reaction monitoring
(MRM) transitions for each peptide. Standard synthetic pep-
tides (2 μM) were infused at 10 μL/min flow rate to optimise
the entrance and the declustering potentials for the three pre-
cursor ions and to choose the best three MRM transitions per
peptide. The collision energy and cell exit potential for each
MRM channel was optimised to maximise signal, and the
most reproducible product ions with high signal intensity were
chosen. Double-charged precursor ions were selected for the
two modified Cys peptides but a single-charge precursor ion
for the marker peptide. Source gases and temperature were
optimised with a T piece in which an infusion of peptide
standards was mixed with 0.1% formic acid acetonitrile
(30%) eluting from the column at 100 μL/min flow rate.
The optimised values for curtain gas, collision gas, GS1 and
GS2 were 10, 12, 30 and 45 (arbitrary unit) respectively. The
heated capillary temperature was maintained at 450 °C and the
ESI voltage was kept at 4200 V.
MRM transitions were monitored and acquired at unit res-
olution in both Q1 and Q3 for the following AGT signature
peptides: (1) AGT marker peptide (SVTQVPF), which was
used to infer the plasma level of total AGT; (2) unlabelled-
IAM alkylated Cys18 and Cys138 peptides, which correspond
to the reduced form of plasma AGT and (3) 13C2,D2-IAM
alkylated Cys18 and Cys138 peptides, which correspond to
the oxidised form of plasma AGT. The final optimised transi-
tions are presented in Table 1. All data were processed by
Analyst software 1.4.2.
The identities of the targeted peptides were confirmed
under similar chromatographic conditions on an ion trap
mass spectrometer coupled to UPLC (LTQ Velos, Thermo
Fisher, San Jose, CA, USA). MS/MS spectra of the pep-
tides of interest were acquired in positive ion data-
dependent mode with parent mass width ± 0.5 and reten-
tion time window 1 min. ESI source parameters were main-
tained as follows: ion spray voltage 3 kV, capillary and
source heater temperatures 275 °C and 300 °C respectively
and flow rate for the sheath, auxiliary and sweep gases 30,
20 and 10 arbitrary units respectively. Data were processed
with Xcalibur 2.2 software (Thermo Fisher Scientific, San
Jose, CA, USA).
Method validation
Quantitative assessment of the developed LC-MS/MSmethod
was carried out by measuring the precision (expressed as co-
efficient of variation, CV%) of six replicate human plasma
samples (for the five monitored peptides). Precision values
of ≤ 15% were considered acceptable, in accordance with
the US-FDA bioanalytical method validation, guidance for
industry, May 2018 [21].
The overall AGT recoveries were calculated by comparing
the peak areas of MRM for the AGT marker peptide from the
plasma digest, with peptide standard spiked into plasma digest
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at the expected concentration of endogenous AGT (45 μg/mL
[22]). Recovery was calculated using the equation below:
recovery ¼ plasma AGT
plasma spiked with AGT peptide standard−plasma AGT
 100%
The linearity of the method was evaluated using an eight-
point calibration line (5 to 400 nM) in plasma chymotryptic
digest using the internal standard method.
To confirm that the method delivered an effective ratio of
the reduced and oxidised forms of AGT, human plasma was
spiked with two precise ratios of the oxidised:reduced AGT
(50:50 and 60:40; similar to the reported ratios in plasma)
using human recombinant glycosylated AGT (3.4 mg/mL in
TRIS buffer (pH 7.4)) expressed in HEK293 cells (all cyste-
ines are in the oxidised form) which was kindly supplied by
MRC group from Cambridge University (Prof. R. Carrell and
Dr. R. Read, Cambridge Institute for Medical Research). To
obtain the reduced form of the protein, human recombinant
AGT standard was fully reduced with 50 mM DTT then
alkylated with 200 mM IAM. Both reactions were carried
out at 37 °C for 30 min in the dark using 10 kDa Amicon
Ultra 0.5. The reduced protein sample was washed twice with
400 μL of TRIS buffer (pH 7.4) at 14,000×g for 7 min to
remove excess reagents.
Figure 2 summarises the workflow followed in this study.
Results and discussion
Analytical strategy
To achieve successful MS analysis and accurate protein redox
measurements, signature peptides should be reproducibly de-
tected [23], and the alkylating agent used to modify the free
thiol of the Cys peptides should have high reactivity, to ensure
reaction completion, without negatively affecting the ionisation
and fragmentation efficiency of the peptide [24]. Therefore, our
method development strategy began by optimising a digestion
protocol for the detection of the key Cys18 and Cys138 pep-
tides, using samples of pure recombinant human AGT.
Different strategies for protein reduction, alkylation and diges-
tion were evaluated to achieve complete AGT digestion and
maximum protein recovery with reliable detection of the mod-
ified Cys peptides. The performance of the deglycosylation
enzyme PNGase F was assessed using SDS-PAGE.
Initial investigations revealed the reproducible detection of
the two key modified Cys peptides with in-solution digestion
using chymotrypsin as proteolytic enzyme and IAM as
alkylating agent (see Electronic Supplementary Material
(ESM) Fig. S1). The identities of the IAM-modified Cys pep-
tides were confirmed by both high-resolution accurate mass
(LC-MS) and peptide fragmentation pattern (LC-MS/MS)
Table 1 The optimised precursor/product ion transitions for iodoacetamide and isotope-labelled iodoacetamide alkylated AGT Cys peptides and the
total AGT marker peptide
Peptide sequence Peptide mass m/z (charge) MS1/MS2 Product ion DP CE
HLVIHDESTC18EQLa
(IAM alkylated, reduced form)
1579.75 790.87 (+ 2) 790.9/725.3 b12
+2 80 36
790.9/844.4 b7 80 40
790.9/1321.6 b11 80 38
790.9/661.3 b11
+2 80 40
HLVIHDESTC18EQLa
(isotope-labelled IAM, oxidised form)
1583.75 792.87 (+ 2) 792.9/727.3 b12
+2 80 36
792.9/844.4 b7 80 40
792.9/1325.6 b11 80 38
792.9/663.3 b11
+2 80 40
KDKDC138TSRLa
(IAM alkylated, reduced form)
1121.57 561.78 (+ 2) 561.8/751.3 y6 65 38
561.8/994.4 y8 65 32
561.8/879.4 y7 65 34
561.8/636.5 y5 65 38
KDKDC138TSRLa
(isotope-labelled IAM, oxidised form)
1125.57 563.78 (+ 2) 563.8/755.3 y6 65 38
563.8/998.4 y8 65 32
563.8/883.4 y7 65 34
563.8/640.5 y5 65 38
SVTQVPF
(AGT marker peptide)
776.41 777.41 (+ 1) 777.4/515.3 b5 75 32
777.4/497.7 b5-H2O 75 30
777.4/480.3 b5-2H2O 75 38
CE collision energy, DP declustering potential, IAM iodoacetamide, MS1/MS2 precursor/product ions
a Peptide sequence after PNGase F processing contains Asp (D) instead of the native Asn (N) due to deglycosylation reaction
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(see ESMFigs. S1 and S2) while complete deglycosylation was
confirmed by band shift on SDS-PAGE (see ESM Fig. S3).
Further work reported below is based on the development
of these initial findings.
Identification of the AGT marker peptide
During our initial experiments with recombinant AGT, a sev-
en amino acid peptide, SVTQVPF, unique in sequence to
AGT was identified from the AGT chymotryptic digest (see
ESM Fig. S2). It was detected as a singly charged ion, having
high signal intensity (higher than both Cys peptides) and mass
accuracy < 1 ppm, making it ideally suited as a signature pep-
tide for the absolute quantification of the total AGT in the
plasma. Furthermore, SVTQVPF shows good electrospray
ionisation and does not contain amino acids which are suscep-
tible to modification, and we refer to SVTQVPF as the ‘AGT
marker peptide’ henceforth.
Detection of the oxidised and reduced forms of AGT
in human plasma
With human plasma, a method for the selective enrichment of
AGT was developed followed by differential alkylation and
digestion of the sample using the optimised protocol. Targeted
LC-MS/MS method working on the MRM mode was used to
detect the key Cys peptides as well as the marker peptide from
the plasma digest (Fig. 2). Combining differential alkylation
of the sample with targeted MS/MS analysis was first used by
Held et al. [12] to quantify the percent oxidation of targeted
Cys from a cellular extract. They termed this approach
OxMRM; quantitative cysteine oxidation analysis by MRM.
Selective enrichment of AGT from human plasma using
ConA/RP-SPE
In identifying AGT eluting fractions, Western blotting re-
vealed AGT detection in more than one fraction, with the
majority eluting at 45% and 48% (v/v) acetonitrile in 0.1%
TFAwater (Fig. 3). Elution of the protein at a range of organic
solvent (acetonitrile in 0.1% TFA) composition is to be ex-
pected with glycoproteins due to the glycan heterogeneity [25,
26]. Human AGT is known to have heterogeneous glycosyl-
ation [27] and so, the result of Western blotting is considered
consistent with glycoprotein heterogeneity and previous stud-
ies conducted on AGT glycosylation.
Reversed-phase fractionation of the lectin affinity extracted
glycoproteins using eight incrementing concentrations of ace-
tonitrile was only necessary for method optimisation pur-
poses. Following the results of Western blotting (Fig. 3), in
actual plasma samples, AGT was subsequently extracted ap-
plying just two-step increments of acetonitrile mobile phase
(acetonitrile in 0.1% TFA water (v/v)). In the first step, 40%
acetonitrile, where very minimal AGTwas evident, was used
to wash the undesired proteins and the other matrix compo-
nents to waste. In the second step, 50% acetonitrile was used
to collect the remaining proteins (in fractions 43, 45, 48 and
50%), which yielded the majority of the AGT.
Reportedly, AGT has been detected directly from the plas-
ma digest without applying any enrichment or depletion ap-
proaches [23, 28–31]; however, different depletion strategies
can significantly improve the detection limit and the reproduc-
ibility of the methods [29, 31]. AGT has been identified with
other plasma glycoproteins by using a multi-lectin approach
[30, 32], and with commercial immune depletion columns,
MARS-7 and MARS-14 [31], ProteoPrep20 [33] and
Seppro® IgY12 coupled with multi-lectins [34]. Although
the previously mentioned enrichment strategies, especially
immunoaffinity depletion columns, offer high reproducibility
and improved in-depth analysis for moderately and low abun-
dant proteins, they are generally associated with high costs
and require long processing times, and there are limitations
associated with non-specific protein binding [31]. Our method
achieved a quick and effective extraction of AGT, as only a
two-step RP-SPE purification was required to capture the ma-
jority of the ConA retained AGT. Therefore, high recovery
and specificity were achieved without reducing throughput,
and a larger number of samples could be processed at a lower
cost per sample compared with immunoaffinity depletion.
Detection of the oxidised and reduced forms of AGT using
differential alkylation and targeted LC-MS/MS
The two distinct redox forms of AGT were detected in human
plasma using the developed targeted LC-MS/MSworkflow and
applying the differential alkylation approach. Differentially
alkylated Cys18 and Cys138 peptides and AGTmarker peptide
with their corresponding MS/MS spectra are presented in
Figs. 4, 5 and 6 respectively.
Fig. 3 Western blotting of human AGT in the eight RP-SPE fractions
using mouse anti-human serpin A8/angiotensinogen antibody. Plasma
glycoproteins were enriched with ConA then fractionated using RP-
SPE where proteins were eluted sequentially with step incrementing
concentrations of acetonitrile in 0.1% TFA in water. High recovery of
plasma AGT was identified, with the majority eluted at 43 to 50%
acetonitrile
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The modified Cys18 peptide showed a higher MS response
and better S/N ratio compared to the modified Cys138 peptide
(Figs. 4 and 5); however, the highest signal intensity was
observed with AGT marker peptide MRM (Fig. 6). This is
consistent with our previous findings using the pure recombi-
nant AGTand with the results obtained from the three peptide
standards (see ESM Fig. S4). The different MS response
among the three peptides is not unexpected. The relative
ionisation and fragmentation of the peptide are dependent on
the sequence, other co-eluting ions and the presence of post
translation modification [25].
With regard to the differentially alkylated Cys peptides,
alkylation with 13C2,D2-IAM introduced a 4-Da increase in
the mass of the singly charged Cys peptides (2 m/z for doubly
charged peptides) compared to the unlabelled alkylated pep-
tide (Figs. 4 and 5). This made the two plasma AGT forms
mass distinguishable when analysed using the targeted LC-
MS/MS method. The differentially alkylated Cys peptides,
which are signatures of the oxidised and the reduced forms
of plasma AGT, exhibited similar physicochemical properties
and therefore were eluted at the same retention time (Figs. 4
and 5). This ensured that the two peptide forms experienced a
similar chemical environment upon analysis, which is crucial
for accurate quantification.
Of importance, both Cys peptides have a potential asparagine
(N) glycosylation site in their sequences: HLVIHNESTC18EQL
and KDKNC138TSRL, and so, effective deglycosylation was
essential for two reasons: firstly, to achieve efficient digestion
and release of the key peptides since glycosylation can inhibit
protease processing. Secondly and more importantly, it is re-
quired to attain the correct parent mass of the peptide in Q1
and thus have the correct mass for MRM transitions. Upon
oligosaccharide cleavage using PNGase F, asparagine is con-
verted to aspartic acid (D) resulting in approximately 1 and
0.5 m/z increase in the singly and doubly charged peptide ions
respectively [25]. Since both modified Cys peptides are doubly
charged, then a further 0.5 m/z was added to the original m/z to
achieve accurate detection of peptides from plasma.
Confirmation of identities of peptides derived from plasma
AGT by LC-MS/MS
Even thoughMRM signals are highly analyte specific, and the
MRM transitions for each peptide were detected at the same
Fig. 4 The extracted ion chromatogram (XIC) of MRM and the corre-
sponding MS/MS spectra for the differentially alkylated Cys18 peptides
detected in a typical human plasma digest. aCys18 peptide alkylatedwith
isotope-labelled 13C2,D2-iodoacetamide representing the oxidised form
of AGT in the plasma. b Cys18 peptide alkylated with unlabelled
13C0,D0-iodoacetamide representing the reduced form of AGT in the
plasma. Peptide identity and differential alkylation were confirmed by
MS/MS spectra
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retention times as the corresponding standard, the identities of
the differentially alkylated Cys peptides and AGT marker
peptide derived from plasma were further confirmed using
LC-MS/MS (Figs. 4, 5 and 6). The amino acid sequence of
detected peptides was interpreted using comprehensive y- and
b-ion series for Cys18 (Fig. 4) and mainly y-ion for Cys138
(Fig. 5), additionally both spectra were similar to their corre-
sponding standards (see ESM Fig. S5). Poor fragmentation
was noticed with the marker peptide (Fig. 6), but was still
comparable with the standard (see ESM Fig. S5). The selected
product ions in MRM transitions for each peptide were appar-
ent in the MS/MS spectra.
Fig. 5 The XIC of MRM and the
correspondingMS/MS spectra for
the differentially alkylated
Cys138 peptides detected in the
plasma digest. a Cys138 peptide
alkylated with isotope-labelled
13C2,D2-iodoacetamide
representing the oxidised form of
AGT in the plasma. b Cys138
peptide alkylated with unlabelled
13C0,D0-iodoacetamide
representing the reduced form of
AGT in the plasma. Peptide
identity and differential alkylation
were confirmed by MS/MS
spectra
Fig. 6 The XIC of MRM and the
corresponding MS/MS spectrum
for AGT marker peptide detected
in the plasma digest of a typical
human plasma sample. Peptide
identity was confirmed by MS/
MS spectrum
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Method performance
A reliable level of 43% (± 2.0%, n = 5) was achieved for the
overall recovery of AGT from the plasma. Calculation of the
variability of the method revealed an acceptable analytical
precision (CV% below 15%) for the two differentially
alkylated Cys18 peptides and the AGT marker peptide
(Table 2), which make them suitable for quantitative protein
measurement in clinical samples in line with the FDA guide-
lines for bioanalytical method validation [21]. Differentially
alkylated Cys138 peptides were associated with low signal
intensity and high variability and were not reproducibly de-
tected between replicates (Table 2) and, therefore, were
deemed not suitable for the quantification of the redox forms
of AGT in the plasma. Hence, the differentially alkylated
Cys18 peptides can be used to infer the oxidation level of
AGT while the marker peptide can be used for the measure-
ment of the total AGT in the plasma. To confirm that the
method delivered an effective ratio of the reduced and
oxidised forms of AGT, we spiked human plasma with two
precise ratios of the oxidised:reduced AGT (50:50 and 60:40;
similar to the reported ratios in plasma) and were able to re-
produce these ratios when the samples were analysed using
the developed method (50.3% ± 1.9% and 58.9% ± 1.6%
representing plasma sample spiked with 50 and 60% oxidised
AGT respectively, n = 3). The MRM assays were free of po-
tential interfering substances at the retention times of the pep-
tides, and no additional peaks were observed when analysing
blank plasma samples, which make the MRM assay specific
and selective for Cys18 and marker peptides.
With regard to the assay of total AGT in the plasma, the
limit of detection (LOD) and the lower limit of quantification
(LLOQ) of the method were 0.5 and 5 nM respectively. The
method showed a linear response in the nanomolar range with
a high correlation coefficient (R2 = 0.992) as seen in the cali-
bration curve in Fig. 7. Analytical throughput requires over-
night protein digestion with 24 sample batches possible with
an LC-MS/MS analysis time of 20 min/sample.
Our method demonstrates reproducible and quantitative
analysis of these important AGT peptides and represents the
first study to use MS workflow to detect the oxidised and the
reduced forms of AGT in human plasma. The two previous
studies that quantified the redox switch of AGT in the plasma
of pre-eclamptic women used either Western blotting or
ELISA [3, 8]. The novel MS workflow we followed is con-
sidered a more reliable quantitative methodology than
Western blotting, used by Zhou et al. [3], which is at best
semi-quantitative. Our developed MS-based methodology
can be applied to accurately quantify the oxidation level of
AGT in clinical samples as a percentage of the sum of the
reduced and oxidised AGT forms. By using this methodology,
we also confirm that changes in AGT levels correlate to
changes in oxidation state rather than total level. This provides
more accurate measurements than the ELISA developed by
Rahgozar et al. [8] where they only detected the reduced form
of AGT, and reported its level as a percentage of that observed
in a pooled standard rather than that of the sum of the two
forms of the protein.
Conclusions
The current work represents the first study to use an MS
workflow to measure the oxidised and reduced forms of
AGT in human plasma. Our methodology uses high-
throughput two-dimensional chromatographic purification
Table 2 The analytical precision
of the developed targeted analysis
for plasma-derived AGT
Protein AGT signature peptide Peptide transition CV% (n = 6)
Oxidised AGT Cys18 peptide alkylated with 13C2,D2-IAM 792.9/727.3 11.1
Cys138 peptide alkylated with 13C2,D2-IAM Sum of three transitions
a 18.7
Reduced AGT Cys18 peptide alkylated with 13C0,D0-IAM 790.9/725.3 9.6
Cys138 peptide alkylated with 13C0,D0-IAM Sum of three transitions
b 27.2
Total AGT Marker peptide 777.4/515.3 6.8
a The transitions are 563.8/640.6, 563.8/755.4 and 563.8/883.4
b The transitions are 561.8/636.5, 561.8/751.3 and 561.8/879.5
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Fig. 7 The linear response of the total AGT assay. Known quantities of
AGT marker peptide standards were spiked in the plasma chymotryptic
digest to generate a calibration plot from 5 to 400 nM. The ratio between
the peak areas of the marker peptide standard and the internal standard
(2 μM NEM alkylated Cys18 peptide) was plotted against AGT marker
peptide standard concentrations. The regression line of the marker AGT
peptide showed a linear response which extends to the low nanomolar
concentrations with a correlation coefficient of R2 = 0.992. Error bars
represent the SD of three technical replicates
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and a differential alkylation strategy coupled with targeted
LC-MS/MS to provide a more reliable and selective quantita-
tive approach than the previously reported antibody-based as-
says used to measure the oxidation level of AGT.
Additionally, our method offers several advantages over
previous redox proteomic studies. It avoids the use of sizable
costly alkylating reagents (e.g. ICAT, biotinylated IAM)
which can limit effective alkylation and the use of highly
denaturing conditions that can facilitate the breakdown of
the disulphide linkage leading to inaccurate quantification.
Additionally, the use of conventional LC-MS/MS as opposed
to a nano-LC system typically used to analyse proteins in
biological samples, makes the method both more applicable
to routine use when high-throughput analysis is required
(20 min run time instead of hours with nano-LC systems),
and more transferable to laboratories not equipped with a
nano-LC system. The extensive sample preparation resulted
in only 43% recovery. However, the workflow was reproduc-
ible and allowed reliable detection of the signature AGT
peptides.
It should be noted that the high complexity of the plasma
(~ 3.3 mg proteins/50 μL plasma) and the presence of sugar
moiety attached to the asparagine residue in both Cys peptides
retarded early effective alkylation directly from the plasma;
consequently, differential alkylation was achieved after pro-
tein enrichment and deglycosylation. Since differential alkyl-
ation was performed following sample preparation, then the
measured levels of oxidation may not accurately reflect those
of AGT in the plasma. However, the developed method will
be applied to compare the relative oxidation level of the pro-
tein between samples from healthy women and those with
developing pre-eclampsia rather than measuring the actual
oxidation level of AGT. In this case, the reproducibility of
the method is paramount, and the demonstrated methodology
showed acceptable analytical precision. This provides a good
level of confidence to move towards the clinical application of
the methodology to quantify the oxidation and total AGT
levels in samples collected from pre-eclamptic and normoten-
sive women.
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